drugset
drugset / Trial / NCT07288567

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

NCT07288567 ↗

Phase 3 Recruiting 166 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

Timeline

Start
2026-01-29
Primary completion
2029-12-18
Completion
2029-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Trospium Small molecule — —

Indications

schizophrenia